Skip to main content
. 2005 Sep 2;4:16. doi: 10.1186/1477-3163-4-16

Figure 1.

Figure 1

The EGFR/MAPK/ERK1/2 signaling pathway. We have previously shown that sulindac metabolites inhibit both MEK1/2 and ERK1/2 activation. The goal of this study was to determine if this inhibition is due to downregulation of the EGFR.